Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
ANTX vs LLY vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
Banks - Diversified
ANTX vs LLY vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General | Banks - Diversified |
| Market Cap | $130M | $1.07T | $896.00B |
| Revenue (TTM) | $0.00 | $72.25B | $280.33B |
| Net Income (TTM) | $-35M | $25.27B | $57.05B |
| Gross Margin | — | 83.5% | 60.0% |
| Operating Margin | — | 45.9% | 25.9% |
| Forward P/E | — | 30.9x | 14.4x |
| Total Debt | $0.00 | $42.50B | $942.38B |
| Cash & Equiv. | $20M | $7.16B | $343.34B |
ANTX vs LLY vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | Jun 26 | Return |
|---|---|---|---|
| AN2 Therapeutics, I… (ANTX) | 100 | 31.5 | -68.5% |
| Eli Lilly and Compa… (LLY) | 100 | 395.6 | +295.6% |
| JPMorgan Chase & Co. (JPM) | 100 | 235.3 | +135.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANTX vs LLY vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANTX has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and defensive.
- Lower volatility, beta 0.42, current ratio 6.87x
- Beta 0.42, current ratio 6.87x
- 189.3% revenue growth vs JPM's 3.3%
LLY is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
- 14.8% 10Y total return vs JPM's 465.8%
- 35.0% margin vs ANTX's 4.7%
JPM is the clearest fit if your priority is income & stability and valuation efficiency.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- PEG 0.81 vs LLY's 1.07
- Lower P/E (14.4x vs 30.9x), PEG 0.81 vs 1.07
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 189.3% revenue growth vs JPM's 3.3% | |
| Value | Lower P/E (14.4x vs 30.9x), PEG 0.81 vs 1.07 | |
| Quality / Margins | 35.0% margin vs ANTX's 4.7% | |
| Stability / Safety | Beta 0.42 vs JPM's 0.94 | |
| Dividends | 1.9% yield, 15-year raise streak, vs LLY's 0.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +319.5% vs JPM's +21.8% | |
| Efficiency (ROA) | 22.7% ROA vs ANTX's -47.3%, ROIC 41.8% vs -61.1% |
ANTX vs LLY vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ANTX vs LLY vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
LLY leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and ANTX operate at a comparable scale, with $280.3B and $0 in trailing revenue. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to JPM's 20.4%.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $0 | $72.2B | $280.3B |
| EBITDAEarnings before interest/tax | -$37M | $34.7B | $81.4B |
| Net IncomeAfter-tax profit | -$35M | $25.3B | $57.0B |
| Free Cash FlowCash after capex | -$31M | $13.6B | $100.9B |
| Gross MarginGross profit ÷ Revenue | — | +83.5% | +60.0% |
| Operating MarginEBIT ÷ Revenue | — | +45.9% | +25.9% |
| Net MarginNet income ÷ Revenue | — | +35.0% | +20.4% |
| FCF MarginFCF ÷ Revenue | — | +18.8% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +17.1% | +169.9% | +16.0% |
Valuation Metrics
JPM leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 68% valuation discount to LLY's 49.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs LLY's 1.71x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $130M | $1.07T | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $110M | $1.11T | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -4.09x | 49.37x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 30.95x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.71x | 0.90x |
| EV / EBITDAEnterprise value multiple | — | 35.38x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | — | 16.42x | 3.20x |
| Price / BookPrice ÷ Book value/share | 2.70x | 38.34x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | 119.31x | 8.88x |
Profitability & Efficiency
LLY leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-52 for ANTX. LLY carries lower financial leverage with a 1.60x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs ANTX's 1/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -52.3% | +101.2% | +15.9% |
| ROA (TTM)Return on assets | -47.3% | +22.7% | +1.3% |
| ROICReturn on invested capital | -61.1% | +41.8% | +4.5% |
| ROCEReturn on capital employed | -56.4% | +46.6% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 8 | 5 |
| Debt / EquityFinancial leverage | — | 1.60x | 2.60x |
| Net DebtTotal debt minus cash | -$20M | $35.3B | $599.0B |
| Cash & Equiv.Liquid assets | $20M | $7.2B | $343.3B |
| Total DebtShort + long-term debt | $0 | $42.5B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 35.68x | 0.74x |
Total Returns (Dividends Reinvested)
LLY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LLY five years ago would be worth $51,207 today (with dividends reinvested), compared to $3,078 for ANTX. Over the past 12 months, ANTX leads with a +319.5% total return vs JPM's +21.8%. The 3-year compound annual growth rate (CAGR) favors LLY at 37.2% vs ANTX's -13.1% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +327.0% | +5.2% | -0.5% |
| 1-Year ReturnPast 12 months | +319.5% | +40.3% | +21.8% |
| 3-Year ReturnCumulative with dividends | -34.4% | +158.2% | +138.2% |
| 5-Year ReturnCumulative with dividends | -69.2% | +412.1% | +118.2% |
| 10-Year ReturnCumulative with dividends | -39.4% | +1484.6% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -13.1% | +37.2% | +33.6% |
Risk & Volatility
Evenly matched — ANTX and LLY each lead in 1 of 2 comparable metrics.
Risk & Volatility
ANTX is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 95.8% from its 52-week high vs ANTX's 68.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.42x | 0.53x | 0.94x |
| 52-Week HighHighest price in past year | $6.91 | $1182.73 | $337.25 |
| 52-Week LowLowest price in past year | $1.00 | $623.78 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +68.6% | +95.8% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 54.5 | 70.0 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 261K | 2.6M | 7.0M |
Analyst Outlook
JPM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ANTX as "Buy", LLY as "Buy", JPM as "Buy". Consensus price targets imply 89.9% upside for ANTX (target: $9) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs LLY's 0.53%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $1268.94 | $339.75 |
| # AnalystsCovering analysts | 8 | 45 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | 11 | 15 |
| Dividend / ShareAnnual DPS | — | $6.00 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% | +3.9% |
LLY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JPM leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
ANTX vs LLY vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ANTX or LLY or JPM a better buy right now?
For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.
7% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AN2 Therapeutics, Inc. (ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ANTX or LLY or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Eli Lilly and Company at 49. 4x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Eli Lilly and Company's 1. 07x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ANTX or LLY or JPM?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.
1%, compared to -69. 2% for AN2 Therapeutics, Inc. (ANTX). Over 10 years, the gap is even starker: LLY returned +1485% versus ANTX's -39. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ANTX or LLY or JPM?
By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.
(ANTX) is the lower-risk stock at 0. 42β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 123% more volatile than ANTX relative to the S&P 500. On balance sheet safety, Eli Lilly and Company (LLY) carries a lower debt/equity ratio of 160% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ANTX or LLY or JPM?
By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.
7% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ANTX or LLY or JPM?
Eli Lilly and Company (LLY) is the more profitable company, earning 31.
7% net margin versus 0. 0% for AN2 Therapeutics, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for ANTX. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ANTX or LLY or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Eli Lilly and Company's 1. 07x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 30. 9x for Eli Lilly and Company — 16. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANTX: 89. 9% to $9. 00.
08Which pays a better dividend — ANTX or LLY or JPM?
In this comparison, JPM (1.
9% yield), LLY (0. 5% yield) pay a dividend. ANTX does not pay a meaningful dividend and should not be held primarily for income.
09Is ANTX or LLY or JPM better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53), 0. 5% yield, +1485% 10Y return). Both have compounded well over 10 years (LLY: +1485%, ANTX: -39. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ANTX and LLY and JPM?
These companies operate in different sectors (ANTX (Healthcare) and LLY (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ANTX is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; JPM is a large-cap deep-value stock. LLY, JPM pay a dividend while ANTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.